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Background: Measles elimination is based on 95% 
coverage with two doses of a measles-containing 
vaccine (MCV2), high vaccine effectiveness (VE) and 
life-long vaccine-induced immunity. Longitudinal anal-
ysis of antibody titres suggests existence of waning 
immunity, but the relevance at the population-level is 
unknown. Aim: We sought to assess presence of wan-
ing immunity by estimating MCV2 VE in different age 
groups (2–5, 6–15, 16–23, 24–30 and 31–42 years) in 
Berlin. Methods: We conducted a systematic literature 
review on vaccination coverage and applied the screen-
ing-method using data from a large measles outbreak 
(2014/15) in Berlin. Uncertainty in input variables was 
incorporated by Monte Carlo simulation. In a scenario 
analysis, we estimated the proportion vaccinated with 
MCV2 in those 31-42 years using VE of the youngest 
age group, where natural immunity was deemed neg-
ligible. Results: Of 773 measles cases (median age: 
20 years), 40 had received MCV2. Average vaccine 
coverage per age group varied (32%–88%). Estimated 
median VE was  > 99% (95% credible interval (CrI): 
98.6–100) in the three youngest age groups, but lower 
(90.9%, 95% CrI: 74.1–97.6) in the oldest age group. In 
the scenario analysis, the estimated proportion vacci-
nated was 98.8% (95% CrI: 96.5–99.8). Conclusion: VE 
for MCV2 was generally high, but lower in those aged 
31-42 years old. The estimated proportion with MCV2 
should have led to sufficient herd immunity in those 
aged 31-42 years old. Thus, lower VE cannot be fully 
explained by natural immunity, suggesting presence 
of waning immunity.
Introduction
Measles is among the most highly transmissible 
infectious diseases known to affect humans and can 
lead to severe complications, such as pneumonia or 
post-infection measles encephalitis [1]. A prior infection 
with measles leads to life-long immunity, however, vac-
cination is the safest means of protection against mea-
sles. In 2012, the World Health Assembly endorsed the 
Global Vaccine Action Plan with the objective to elimi-
nate measles in five of six World Health Organization 
(WHO) regions by 2020 [2]. Germany and the WHO 
European Region have committed to this goal [3,4]. 
Elimination is defined as the absence of endemic trans-
mission in a country or defined geographical region for 
more than 36 months under a well-performing surveil-
lance system [5]. Mathematical modelling indicates 
that a population immunity of up to 94% (via natural 
immunity or via vaccination) is necessary to reach herd 
immunity sufficient for elimination [6]. In the WHO 
European Region, the indicators for measuring progress 
towards measles elimination are vaccination coverage 
and measles incidence. The goal is to maintain at least 
95% coverage with two doses of a measles-containing 
vaccine (MCV) at a national level and a measles inci-
dence of less than one case per million population [3].
Since the introduction of case-based measles surveil-
lance in Germany in 2001, the target goals for elimina-
tion were not met [7]. In Berlin, the capital of Germany 
with around 3.6 million inhabitants and a high popu-
lation density, high incidences (range 5-145 cases per 
million population) have been observed from 2001 
through 2013. The largest measles outbreak occurred 
from October 2014 to August 2015 and included a total 
of 1,344 measles cases in all 12 districts of Berlin, with 
an attack rate of 309 cases per million population [8].
Vaccination with a single dose of MCV (MCV1) was 
introduced in Germany in the early 1970s, followed 
with a two-dose scheme (MCV2) introduced in 1983 
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in the former German Democratic Republic and 1991 
in the reunited Germany [9]. Since 2001, the standing 
committee on vaccination in Germany recommends the 
first immunisation with MCV between 11 and 14 months 
and the second immunisation between 15 and 23 
months. Since 2010, a catch-up vaccination is recom-
mended for all adults born after 1970 who are unvac-
cinated, have an unknown vaccination status or have 
only been given a single dose of MCV in their childhood 
[10]. Vaccination is voluntary and covered by insurance 
companies. There is no central vaccination register in 
Germany, so vaccination coverage is estimated based 
on health insurance data, school entry examinations 
and representative studies [11].
Current vaccination strategies assume that vaccination 
against measles leads to life-long immunity. However, 
laboratory analysis of serum samples from vaccinated 
persons living in areas of low endemicity show that 
antibody titres decrease over time, a phenomenon 
described as waning immunity [12-14], which could 
eventually lead to secondary immune failure. To evalu-
ate the impact of this phenomenon on global elimina-
tion strategies, vaccine effectiveness (VE) has to be 
re-evaluated in countries close to elimination, with a 
special focus on older age groups where waning immu-
nity would be most pronounced. The screening method 
based on Farrington’s work [15] allows VE to be esti-
mated in the field, but it requires a valid estimate of 
the vaccination coverage in the general population. 
Thus, it is mostly used in countries with a central vac-
cination registry.
The main objective of our study was to estimate age-
specific VE for MCV2 and investigate the presence of 
waning immunity, by applying the screening method 
on data from a large measles outbreak that occurred 
in Berlin 2014/15. In addition, we aimed at quantifying 
uncertainty in VE-estimates and the underlying input 
parameters, e.g. proportion of the population vacci-
nated (PPV) to inform further research.
Methods
We modelled vaccine effectiveness by use of the 
screening method, an observational study type that 
uses the entire population as the reference for the 
proportion of the population vaccinated. The input 
parameters came from a retrospective outbreak analy-
sis and from a literature review. Input parameters were 
described as distributions to accommodate for imper-
fect knowledge of the true parameters and modelled 
using Monte Carlo simulation.
Data sources
Vaccination status of measles cases
We used notification data from a large measles out-
break in Berlin 2014/15 [8] and included all confirmed 
measles cases among the resident population of Berlin 
with a known vaccination status. Vaccination dose and 
date of last vaccination, as marked in the notification 
database, were obtained by local health authorities via 
vaccination records or attending physicians. Prior to 
analysis, entries for twice-vaccinated cases (fully vac-
cinated) were reviewed for accuracy with local health 
authorities. To exclude post-exposure vaccinations 
(≤ 14 days before disease onset) the time between last 
vaccination dose and disease onset was calculated.
Data editing and descriptive analysis of case charac-
teristics was performed with STATA 13.1 (StataCorp 
LLC, Texas, United States). We calculated proportions 
or median values and interquartile ranges (IQR) as 
appropriate and conducted further analyses separately 
for five different age groups (2–5, 6–15, 16–23, 24–30 
and 31–42 years).
Vaccination coverage
In this study, we determined vaccination coverage of 
children younger than 6 years of age using data from 
the association of statutory health insurance physi-
cians [16]. Vaccination coverage of children aged 6–15 
years was determined using data from school entrance 
Table 1
Number of measles cases in the residential population with known vaccination status during a large outbreak, by age group 




MCV1 MCV2 Unknown number of doses Total
n % n % n % n % n % n
2–5 6 6.98 2 2.33 1 1.16 9 10.47 77 89.53 86
6–15 1 0.52 5 2.59 4 2.07 10 5.18 183 94.82 193
16–23 6 3.49 7 4.07 1 0.58 14 8.14 158 91.86 172
24–30 11 7.05 13 8.33 2 1.28 26 16.67 130 83.33 156
31–42 18 10.84 13 7.83 4 2.41 35 21.08 131 78.92 166
Total 42 5.43 40 5.17 12 1.55 94 12.16 679 87.84 773
MCV: measles-containing vaccine.
Ages included are 2–42 years.
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health examinations that are published annually in the 
national bulletin for infectious diseases of the Robert 
Koch-Institute (RKI) [17]. For the two-dose scheme of all 
age cohorts older than 15 years, we conducted a sys-
tematic literature search for representative surveys. 
The National Center for Biotechnology Information 
database ‘PubMed’ was searched using the terms 
‘vaccination coverage’, ‘measles’ and ‘Germany’. In 
addition, internal databases on the RKI website were 
searched for publications about vaccination coverage 
in the German adult population. Studies included in 
the analysis were any with a target population older 
than 15 years, representative of the target population 
and differentiated between the number of vaccination 
doses.
Vaccine effectiveness estimation
Age groups were constructed based on plausibility and 
data availability. The lower limit of 2 years was chosen 
because vaccination with MCV2 is recommended to be 
completed shortly before 2 years of age. An upper limit 
of 42 years was chosen due to lack of data on dose-
specific vaccination coverage for the population older 
than 42 years. The age group 2–5 years is covered 
by insurance claims data and the age group 6–15 by 
school entry exams. For persons aged 23 and younger 
two doses of MCV were recommended in Germany 
since 1991 and for persons younger than 31 years of age 
two doses were recommended in the former German 
Democratic Republic since 1983.
VE of MCV2 was estimated with the screening method 
[15], which compares the vaccination coverage of cases 
(proportion of cases vaccinated (PCV)) with that of the 
general population (proportion of the population vacci-
nated (PPV)) using the formula VE = 1-((PCV/(1-PCV))*(1-
PPV)/PPV). Dose-specific values for the PPV with two 
doses (PPV2) and the PCV with two doses (PCV2) were 
calculated as described elsewhere [18]. Briefly, PCV2 
and PPV2 were calculated using only MCV2 and unvac-
cinated individuals, i.e. excluding individuals with 
MCV1. Point-estimates of PCV were computed from 
data from the outbreak described above. Point esti-
mates for PPV for each age group were averaged over 
single years’ estimates and weighted with the rela-
tive population size of the single age cohort in Berlin 
[19]. If more than one result was available for an age 
cohort, studies were weighted equally and the average 
was used in the calculation. To display the uncertainty 
about the correct estimate, PPV was represented as a 
PERT distribution, a parametric distribution that has 
been adapted to model expert opinions by requiring 
only a minimum, maximum and most likely value. The 
minimum and maximum values in the distribution were 
chosen by the lowest and highest values from the sin-
gle estimates within a specific age group. PCV was rep-
resented as a beta distribution. Uncertainty of the two 
input variables (PCV and PPV) was incorporated into 
the final VE estimates by performing Monte Carlo simu-
lation with 10,000 iterations employing Monte Carlo 
sampling; 95% credible intervals (95% CrI) were calcu-
lated. The software ModelRisk (Vose Sint-Amandsberg, 
Belgium) was used for analysis.
The screening method assumes absence of natural 
immunity because its presence would reduce the pro-
portion of unvaccinated susceptible persons and thus 
lead to an underestimation of PPV and consequently 
VE. The extent of natural immunity in the adult popu-
lation of Berlin is unknown but assumed to be pre-
sent. We aimed to evaluate the likelihood that natural 
immunity exclusively explains the reduced VE in the 
oldest age group (31–42 years), if waning immunity 
is excluded as contributing factor. Therefore, we con-
ducted a scenario analysis by estimating PPV2 in this 
age group using the estimated distribution of VE from 
the youngest age group, where we deemed the pres-
ence of natural immunity to be negligible. If natural 
immunity would be the only contributing factor to a 
lower estimation for VE, the computed proportion sus-
ceptible needed to be large enough (i.e. PPV2 must be 
small enough) to encompass a natural immune popula-
tion and a truly susceptible population in which mea-
sles could have spread (i.e. >5%, ignoring susceptible 
population stemming from imperfect VE of MCV1). To 
this end, the equation of the screening method was 
solved for PPV: PPV = PCV/(1 - VE + PCV*VE); Monte 
Carlo simulation was used as described above.
Table 2




Number of cases with MCV2 Number of cases with vaccination date
Median years between disease onset and second 
vaccination (IQR)
2–5 2 2 3 (2.8–3.2)
6–15 5 3 8.7 (2.4–10.9)
16–23 7 5 12.5 (12.2–15.7)
24–30 13 9 24.1 (23.1–27)
31–42 13 7 30.5 (27.9–30.6)
Total 40 26 21.6 (12.2–27.9)
IQR: Interquartile range; MCV: measles-containing vaccine.
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Ethical statement
Within the framework of the German Infection 
Protection Act, the State Office for Health electroni-
cally receives de-identified data on cases of notifiable 
infectious diseases from local health authorities. Thus, 
a review by an ethics committee was not required.
Results
During the 2014/15 measles outbreak in Berlin [8], a 
total of 1,344 measles cases were notified. Of those, 
773 cases (428 male and 345 female; age range 2–42 
years) from the residential population with known vac-
cination status were included in the analysis in five 
different age groups. (Table 1). Post exposure vacci-
nations (MCV1: n = 32, MCV2: n = 3) were subtracted 
from the total number of vaccinations received, leav-
ing 679 measles cases (87.8%) with no vaccination, 42 
(5.4%) with MCV1, 40 (5.2%) with MCV2 and 12 (1.6%) 
with unknown vaccination dose. The proportion of 
cases with MCV2 was higher for those aged 23 years 
and older. Vaccination dates were provided for 65% 
Table 3
Data source and type for determination of vaccination coverage, vaccination coverage and proportion of the population 


























3 3 2016 Berlin [16] ASHIP 0.120 0.858 0.845 0.975
4 4 2017 Berlin [16] ASHIP 0.079 0.906 0.840 0.984
5 5 2017 Berlin [16] ASHIP 0.072 0.913 0.828 0.984
6–15




7 6 2013 Berlin [17] SEE 0.052 0.908 0.565 0.958
8 6 2012 Berlin [17] SEE 0.050 0.909 0.549 0.957
9 6 2011 Berlin [17] SEE 0.052 0.907 0.559 0.957
10 6 2010 Berlin [17] SEE 0.057 0.897 0.553 0.951
11 6 2009 Berlin [17] SEE 0.060 0.891 0.550 0.948
12 6 2008 Berlin [17] SEE 0.070 0.882 0.593 0.948
13 6 2007 Berlin [17] SEE 0.077 0.868 0.583 0.940
14 6 2006 Berlin [17] SEE 0.102 0.836 0.622 0.931
15 6 2005 Berlin [17] SEE 0.147 0.788 0.693 0.924
15–18 7–10 2006 Germany [21] Survey 0.166 0.780 0.755 0.935
16–23




19–21 11–13 2006 Germany [21] Survey 0.182 0.756 0.746 0.924
21–22 18–19 2011 Schleswig-Holstein [22] Survey 0.083 0.771 0.362 0.841
22–25 14–17 2006 Germany [21] Survey 0.165 0.775 0.733 0.928
23–32 20–29 2011 Schleswig-Holstein [22] Survey 0.249 0.589 0.606 0.784
24–30




23–32 20–29 2011 Schleswig-Holstein [22] Survey 0.249 0.589 0.606 0.784
24–28 22–26 2012 Rhineland-Palatinate [20] Survey 0.235 0.745 0.922 0.974
29–33 30–31 2012 Rhineland-Palatinate [20] Survey 0.450 0.525 0.947 0.955
31–42




29–33 30–31 2012 Rhineland-Palatinate [20] Survey 0.450 0.525 0.947 0.955
33–42 30–39 2011 Schleswig-Holstein [22] Survey 0.238 0.200 0.742 0.679
34–38 32–36 2012 Rhineland-Palatinate [20] Survey 0.480 0.353 0.298 0.262
ASHIP: association of statutory health insurance physicians; MCV: measles-containing vaccine; PPV: proportion of the population vaccinated; 
SEE: school entry exam.
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of cases with MCV2. Double checking of vaccination 
dates and doses together with the LHA revealed no 
erroneous inputs.
The median time span since last vaccination (Table 
2) indicated that most cases were vaccinated during 
childhood as recommended. Due to this, we used age 
as a proxy for the time since last vaccination.
The literature search for vaccination coverage with 
MCV in Germany resulted in 76 hits of which, 66 were 
excluded as they did not address vaccination cover-
age for MCV or referred to an already-included study. 
We identified 10 studies, which we reviewed in detail 
– two studies were excluded as the study population 
was too young, one was excluded for not differentiating 
between number of vaccination doses and four were 
excluded for an unrepresentative study population 
(e.g. healthcare workers or medical students). In total, 
three studies were included in the final model [20-
22]. Knowledge gaps for vaccination coverage in the 
population older than 15 years, especially concerning 
dose-specific information, were identified. Estimates 
for these groups relied on representative surveys that 
were collected in other states of Germany [20,22] or for 
the entire country [21], thus they were not specific to 
Berlin.
Estimated vaccine coverage for MCV2 by age group 
varied from 32–88% (Table 3). The PPV2 values in the 
age groups under 16 years were similar, had narrow 
95% Crls (2–5 years: 95% CrI: 96–98 and 6-15 years: 
95% CrI: 93–96) and median values were above 94% 
(Figure 1A). The 95% CrI of PPV2 distributions for the 
age groups 24–30 years and 31–42 years were wider 
(95% Crl: 81–95 and 33–80, respectively), indicating 
greater uncertainty. PCV should positively correlate 
with vaccine coverage provided that the effect of nat-
ural immunity is constant across age groups and that 
vaccine-induced immunity does not wane. As already 
suggested from the raw data (Table 1), PCV2 point esti-
mates were higher in the age groups above 24 years 
(Figure 1B) with a median PCV2 of 9.4% (95% CrI: 
5.4–14.8) compared to the younger age groups with a 
median PCV2 below 5% (95% CrI: 0.8–8.8). 
The resulting distributions representing VE estimates 
for the five age groups showed a decline in VE with 
increasing age. VE estimates in the three younger age 
groups (2–23 years) were all above 99% (Figure 2). The 
estimated VE in the age group 24–30 years was slightly 
lower with a median of 98.5% (95% CrI: 97–99.5). The 
estimate for the oldest age group (31–42 years) was 
lower with a median of 90.9% (95% CrI: 74.1–97.6).
In a scenario analysis evaluating the possible influence 
of natural immunity, the estimated PPV for the age 
group 31–42 years was substantially higher (median: 
98.8%; 95% CrI: 96.5–99.8) than estimated from the 
literature review (median: 52.9%; 95% CrI: 33.2–79.9) 
(Figure 3).
Discussion
Using notification data from a large measles outbreak 
in Berlin in 2014/15, we estimated VE for MCV2 in differ-
ent age groups to investigate signs of waning immunity 
in the population of Berlin. The existence of such an 
effect at the population level could have implications 
for vaccination recommendations and future elimina-
tion strategies.
A high median VE of over 99% for those aged 2–23 
years for MCV2 was estimated with low uncertainty 
in this study. In a literature review, VE across studies 
Figure 1
Probability distributions representing the estimated 
(A) proportion of the population vaccinated and (B) 
proportion of cases vaccinated with MCV2, by age group, 
Berlin, October 2014–August 2015
A. Proportion of the population vaccinated
B. Proportion of cases vaccinated with MCV2
Estimated PPV for MCV2































MCV: measles-containing vaccine; PCV: proportion of cases 
vaccinated; PPV: proportion of the population vaccinated.
Boxes represent the interquartile range. The median is marked by a 
black line and the whiskers represent the range from p2.5 to p97.5. 
Outliers are marked as black points.
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has been averaged to be 94.1% [23]. Notification data 
capture only a fraction of actual cases occurring in 
the population, likely disproportionately severe cases 
and those with a typical clinical presentation. Patients 
who have been vaccinated usually present with milder 
and fewer symptoms and are therefore presumably 
under-ascertained in notification data. This may have 
resulted in an underestimation of PCV and an over-
estimation of VE in this study. When re-analysing the 
data, assuming a fourfold under-ascertainment of PCV, 
VE was still greater than 99% in the two youngest age 
groups (2–5 years and 6–15 years, data not shown), 
suggesting that the biasing effect of under-ascertained 
modified measles is limited. A case–control study per-
formed in a different region in Germany during a large 
school outbreak in 2006 [24] (also included in the lit-
erature review) resulted in a VE estimate for MCV2 of 
more than 99% in persons aged 10–21 years. To reach 
required herd immunity of more than 94% [6], such a 
high VE would be necessary to actually enable elimi-
nation under the proviso of a 95% two-dose coverage 
strategy as recommended by WHO.
We observed a reduction of VE with increasing age and 
a markedly lower VE in persons 31–42 years of age, 
which could be a sign for waning immunity. Our results 
are consistent with previously published modelling 
approaches based on serology, that estimated the mean 
duration of vaccine-induced protection by MCV1 to be 
25 years in the absence of re-exposure [25]. However, 
VE estimation by the screening method is affected by 
the proportion of prior cases (i.e. those with natural 
immunity) in the population under analysis, especially 
if the cases are distributed unevenly across age groups 
[26]. Measles is notifiable in Germany since 2001 and 
no reliable data have been published about the propor-
tion of people with natural immunity in different age 
cohorts; this is particularly important for cohorts born 
before 2001 as this population showed signs of waning 
immunity in our study.
Before 1990, measles mortality, which can be used to 
estimate measles incidence, decreased gradually over 
time in the former Federal Republic of Germany [9]. It 
is assumed that the proportion of the population with 
natural immunity is higher in older age groups, poten-
tially leading to an underestimation of VE, as there are 
less susceptible individuals in the population, which 
would result in an underestimation of the true PPV. 
Therefore, it remains unclear whether the reduced VE in 
the oldest age group is a result of vaccine-induced wan-
ing immunity, a high proportion of natural immunity 
or a mixture of both. Assuming that VE was constant 
with 99% across all age groups i.e. no waning immu-
nity, we would have expected to observe no more than 
one measles case (instead we observed 14 cases) with 
MCV2 in the oldest age group, which would result in a 
decrease of measles cases in this outbreak by around 
1%. To evaluate the potential presence of waning immu-
nity we chose an indirect approach by computing PPV 
under the assumption that natural immunity would be 
the sole cause for reduced VE. PPV values cannot be 
directly translated into vaccination coverage without 
further knowledge about the coverage with all other 
doses. A value of almost 99% would indicate a very 
small susceptible population in the age group 31–42 
years and, if this was true, measles should not have 
been able to spread in this population. Taking the pop-
ulation with only one dose of MCV into consideration, 
the susceptible population would be even smaller than 
estimated in the scenario analysis. The large number 
of cases in this age group and the high median age of 
17 years in this outbreak, however, contradict the very 
low proportion of susceptible people in the oldest age 
group. Therefore, even though natural immunity might 
have influenced our VE estimates in older age groups, 
it is insufficient to explain the full reduction of VE in 
this age group.
Figure 2
Estimated vaccine effectiveness for MCV2, by age group, 




Estimated VE for MCV2
Estimated VE for MCV2




























MCV: measles-containing vaccine; VE: vaccine effectiveness.
Boxes represent the interquartile range. The median is marked by a 
black line and the whiskers represent the range from p2.5 to p97.5. 
Outliers are marked as black points. Panel A depicts all five age 
groups; panel B depicts a more detailed view of only the first four 
age groups.
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Vaccination registries are viewed as the gold stand-
ard to monitor vaccination coverage [27]. In Germany 
without such registries, there was a big discrepancy 
between the quality of data for vaccination cover-
age in younger and older age groups in this study. 
Even though data from statutory health insurance and 
school entry exams gave a very detailed picture of vac-
cination coverage in children (2-15 years), vaccination 
coverage data for those older than 15 years was scarce. 
The data specific for vaccination doses in the popula-
tion older than 24 years were derived from a telephone 
survey, which was carried out in 2012 in Rhineland-
Palatinate [20] and a study carried out during routine 
occupational health checks in Schleswig-Holstein in 
2011 [22] (both rural areas non-adjacent to Berlin). It 
is not clear how well these regions represent the mul-
ticultural and metropolitan environment of Berlin with 
its many temporary visitors and long-term immigrants 
(this would also be insufficiently covered in a cen-
tral vaccination registry). In addition, the two studies 
yielded very different estimates for vaccination cover-
age in the adult population. The resulting uncertainty, 
especially for those aged 31–42 years, is reflected in 
the broad distributions for PPV.
Combining the screening method with Monte Carlo 
simulation, allowing the incorporation of uncertainties, 
may become an attractive alternative for countries 
that do not have a central vaccination registry, such 
as Germany. It allows to directly identify and quantify 
knowledge gaps (e.g. for vaccination coverage in cer-
tain age groups) and the model can be easily adapted 
to the current level of knowledge.
Aside from the potential under-ascertainment of modi-
fied measles mentioned above, our study is subject to 
at least two limitations. First, the screening method 
assumes absence of natural immunity, which is unreal-
istic in the population studied particularly in the older 
age groups; this may have resulted in an underestima-
tion of VE in the older age groups. Although we inves-
tigated the effect indirectly in a scenario analysis, we 
were not able to quantify the proportion of naturally 
immune in the adult population to adjust our VE esti-
mates. A serosurvey, which additionally assesses the 
vaccination status of the participants, could be an 
important add-on to obtain a reliable estimate about 
the immune status of the population. Second, vacci-
nation dates were available for only 65% of all twice-
vaccinated cases and only for seven of 13 cases in the 
oldest age group. Misclassification of vaccinated and 
unvaccinated cases could influence estimates for VE. 
Re-analysing the data for the oldest age group with 
only seven instead of 13 MCV2 cases we obtained 
an estimate for VE of 95% (data not shown), which is 
higher but still markedly lower than in the other four 
age groups.
Results of our population-based study, in keeping with 
serological studies [12-14], suggest the existence of 
a waning immunity of the measles vaccine. Although 
measles cases have gradually declined globally since 
the 1980s together with an increase in vaccination cov-
erage [1], there has been a resurgence of measles in 
the European Union and European Economic Area start-
ing in 2017 with adults aged ≥20 years comprising more 
than a third of all cases [28]. The impact of waning 
immunity to measles will likely become more apparent 
over the coming years and may increase in the future, 
as the vaccinated population (with hardly any exposure 
to measles) will grow older and the time since vaccina-
tion increases. It is worth noting that the median age 
of measles cases has been increasing over the past 15 
years in Berlin [8] and the extent of waning immunity 
may increase further. Vaccinated cases have a lower 
viraemia and have rarely been observed to contribute 
to transmission [29,30]. However, with the vaccinated 
population turning older and titres possibly decreasing 
further, this observation has to be re-evaluated. This 
is of note, as the age group showing signs of waning 
immunity comprises individuals likely to have a young 
family with children, who may be too young for vaccina-
tion. In order to eliminate measles it will be crucial to 
regularly measure VE with a special focus on adults.
Increasing population mobility will necessitate a regu-
lar assessment of the immune status, particularly of 
the adult population, even in countries with a vaccina-
tion registry. The differentiation between natural and 
waning immunity and their effect on VE will provide 
information for the development of future vaccination 
recommendations. In response to an increase in mea-
sles cases in twice-vaccinated individuals, Taiwan now 
recommends an additional dose of measles vaccine 
for healthcare workers and aircraft staff despite high 
immunisation rates with two doses [31].
Figure 3
Comparison of PPV for the age group 31–42 years using 
VE as determined through literature review and VE 

























Estimated PPV for MCV2
1.00.90.80.70.60.50.40.30.20.10.0
MCV: measles-containing vaccine; PPV: proportion of the 
population vaccinated; VE: vaccine effectiveness.
Boxes represent the interquartile range. The median is marked by a 
black line and the whiskers represent the range from p2.5 to p97.5. 
Outliers are marked as black points.
8 www.eurosurveillance.org
In conclusion, although we detected signs of waning 
immunity in the population of Berlin, we do not believe 
that vaccination recommendations should be altered 
at this point. Our data suggest that only a small per-
centage (maximum 1%) of cases could be ascribed to 
waning immunity and such cases are unlikely to con-
tribute to further spread. The methodology presented 
here, which incorporates uncertainty into the screening 
method, provides a useful tool to monitor VE in coun-
tries getting closer to measles elimination with well-
vaccinated birth cohorts growing older.
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